دورية أكاديمية
Heavy Chain Constant Region Usage in Antibodies to Peptidylarginine Deiminase 4 as a Marker of Disease Subsets in Rheumatoid Arthritis.
| العنوان: | Heavy Chain Constant Region Usage in Antibodies to Peptidylarginine Deiminase 4 as a Marker of Disease Subsets in Rheumatoid Arthritis. |
|---|---|
| المؤلفون: | Gómez-Bañuelos E; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland., Shi J; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland., Wang H; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland., Danila MI; Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham., Bridges SL Jr; Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham., Giles JT; Division of Rheumatology, College of Physicians and Surgeons, Columbia University, New York., Sims GP; BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland., Andrade F; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland., Darrah E; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland. |
| المصدر: | Arthritis & rheumatology (Hoboken, N.J.) [Arthritis Rheumatol] 2022 Nov; Vol. 74 (11), pp. 1746-1754. Date of Electronic Publication: 2022 Sep 29. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley Country of Publication: United States NLM ID: 101623795 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2326-5205 (Electronic) Linking ISSN: 23265191 NLM ISO Abbreviation: Arthritis Rheumatol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Malden, MA : Wiley, [2014]- |
| مواضيع طبية MeSH: | Arthritis, Rheumatoid*, Humans ; Protein-Arginine Deiminases ; Protein-Arginine Deiminase Type 4 ; Autoantibodies ; Biomarkers ; Immunoglobulin G ; Immunoglobulin E |
| مستخلص: | Objective: The study of autoantibody isotypes in autoimmune diseases is useful for identifying clinically relevant endotypes. This study was undertaken to study the prevalence and clinical significance of different isotypes and IgG subclasses of anti-peptidylarginine deiminase 4 (anti-PAD4) autoantibodies in individuals with rheumatoid arthritis (RA). Methods: In 196 RA subjects and 64 healthy controls, anti-PAD4 antibody types were determined using enzyme-linked immunosorbent assay. We investigated associations between anti-PAD4 antibodies and clinical outcomes, and relevant features were confirmed in an independent RA cohort. Results: Anti-PAD4 IgG1, anti-PAD4 IgG2, anti-PAD4 IgG3, anti-PAD4 IgG4, anti-PAD4 IgA, and anti-PAD4 IgE antibodies were more frequent in RA patients than healthy controls (P < 0.001). Anti-PAD4 IgG1, anti-PAD4 IgG3, and anti-PAD4 IgE were associated with distinct clinical features. Anti-PAD4 IgG1 was predictive of progressive radiographic joint damage (odds ratio [OR] 4.88, P = 0.005), especially in RA patients without baseline joint damage (40% versus 0%, P = 0.003) or in those negative for anti-cyclic citrullinated peptide and/or rheumatoid factor (OR 32; P = 0.009). IgG1 was also associated with higher levels of C-reactive protein (P = 0.006) and interleukin-6 (P = 0.021). RA patients with anti-PAD4 IgG3 had higher baseline joint damage scores (median Sharp/van der Heijde score 13 versus 7, P = 0.046), while those with anti-PAD4 IgE had higher Disease Activity Score in 28 joints (median 4.0 versus 3.5, P = 0.025), more frequent rheumatoid nodules (31% versus 16%, P = 0.025), and more frequent interstitial lung disease (ground-glass opacification) (24% versus 9%, P = 0.014). Anti-PAD4 IgG1 antibody associations with joint damage were corroborated in an independent RA cohort. Conclusion: Anti-PAD4 IgG1, anti-PAD4 IgG3, and anti-PAD4 IgE antibodies identify discrete disease subsets in RA, suggesting that heavy chain usage drives distinct effector mechanisms of anti-PAD4 antibodies in RA. (© 2022 American College of Rheumatology.) |
| References: | Pathog Dis. 2013 Apr;67(3):206-13. (PMID: 23620184) Nat Rev Immunol. 2017 Jan;17(1):60-75. (PMID: 27916980) Ann Rheum Dis. 2009 Feb;68(2):249-52. (PMID: 18723564) Bioinformatics. 2014 Oct;30(19):2811-2. (PMID: 24930139) J Rheumatol. 2008 Jun;35(6):969-74. (PMID: 18398945) Autoimmun Rev. 2016 Jul;15(7):776-80. (PMID: 26997641) Arthritis Rheum. 1988 Mar;31(3):315-24. (PMID: 3358796) BMC Bioinformatics. 2019 Dec 24;20(Suppl 15):644. (PMID: 31874610) Sci Transl Med. 2013 May 22;5(186):186ra65. (PMID: 23698378) Antibodies (Basel). 2016 Jan 04;5(1):. (PMID: 31557984) Hum Mol Genet. 2019 Mar 1;28(5):858-874. (PMID: 30423114) Nat Rev Rheumatol. 2012 Oct;8(10):573-86. (PMID: 22907289) Arthritis Rheum. 2010 Jun;62(6):1583-91. (PMID: 20155830) Arthritis Care Res (Hoboken). 2010 May;62(5):624-31. (PMID: 20461784) Arthritis Res Ther. 2016 Oct 22;18(1):241. (PMID: 27770831) Arthritis Rheum. 2008 Jun 15;59(6):807-15. (PMID: 18512711) Nat Immunol. 2016 Feb;17(2):196-203. (PMID: 26692173) J Rheumatol. 2002 Jan;29(1):62-7. (PMID: 11824973) Arthritis Rheum. 2000 Dec;43(12):2751-61. (PMID: 11145033) Front Immunol. 2014 Oct 20;5:520. (PMID: 25368619) J Rheumatol. 2012 Apr;39(4):694-700. (PMID: 22382335) PLoS One. 2014 Jun 05;9(6):e98794. (PMID: 24901704) PLoS One. 2013;8(4):e61045. (PMID: 23577190) Front Immunol. 2018 Nov 20;9:2696. (PMID: 30515171) Clin Rheumatol. 2011 Apr;30(4):563-7. (PMID: 21210288) Clin Rheumatol. 2015 Oct;34(10):1697-704. (PMID: 26242470) J Rheumatol. 2003 Dec;30(12):2585-9. (PMID: 14719198) Bioinformatics. 2016 Sep 15;32(18):2847-9. (PMID: 27207943) J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):S41-52. (PMID: 20176268) Arthritis Rheum. 1995 Jan;38(1):44-8. (PMID: 7818570) J Rheumatol. 2000 Jan;27(1):261-3. (PMID: 10648051) J Rheumatol. 2018 Aug;45(9):1211-1219. (PMID: 29858238) Arthritis Res Ther. 2021 Jun 6;23(1):163. (PMID: 34092252) Nat Rev Rheumatol. 2020 Jun;16(6):301-315. (PMID: 32341463) |
| معلومات مُعتمدة: | R01 AR069569 United States AR NIAMS NIH HHS; R21 AR079891 United States AR NIAMS NIH HHS; R01 AR079404 United States AR NIAMS NIH HHS; R01 AR050026 United States AR NIAMS NIH HHS |
| المشرفين على المادة: | EC 3.5.3.15 (Protein-Arginine Deiminases) EC 3.5.3.15 (Protein-Arginine Deiminase Type 4) 0 (Autoantibodies) 0 (Biomarkers) 0 (Immunoglobulin G) 37341-29-0 (Immunoglobulin E) |
| تواريخ الأحداث: | Date Created: 20220608 Date Completed: 20221101 Latest Revision: 20231102 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC9617771 |
| DOI: | 10.1002/art.42262 |
| PMID: | 35675168 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2326-5205 |
|---|---|
| DOI: | 10.1002/art.42262 |